Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345818 | 1.00 | PIM2 (0.43) | PIM2PTGS2RHOATHRBHTT | |
| SCHEMBL3452877 | 0.88 | CDK2 (0.40) | EGFRCDK2CDK9 | |
| SCHEMBL3449534 | 0.87 | RIPK2 (0.45) | PIM2PTGS2RHOATHRBHTT | |
| SCHEMBL3449538 | 0.87 | RIPK2 (0.45) | PIM2PTGS2RHOATHRBHTT | |
| SCHEMBL3344327 | 0.87 | PIM2 (0.40) | PIM2RHOAEGFRAURKA | |
| SCHEMBL3344324 | 0.87 | PIM2 (0.40) | PIM2RHOAEGFRAURKA | |
| SCHEMBL3452880 | 0.85 | PTGS2 (0.38) | PTGS2EGFRPTK2CCNT1CCNE1 | |
| SCHEMBL3452005 | 0.84 | THRB (0.46) | PIM2PTGS2RHOATHRBHTT | |
| SCHEMBL3452002 | 0.84 | THRB (0.46) | PIM2PTGS2RHOATHRBHTT | |
| SCHEMBL3452879 | 0.80 | PTK2 (0.38) | PTGS2PTK2CCNT1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | PIM2 3060/4885PTGS2 355/4885RHOA 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.